12:00 AM
Dec 17, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

GWP42004: Phase IIa data

A 5-arm, double-blind, placebo-controlled, exploratory Phase IIa trial in 62 Type II diabetics showed that twice-daily 5 mg GWP42004 led to no improvement on the primary endpoint of increasing HDL-C levels from baseline to week 13. GWP42004 did significantly reduce FPG (p=0.04), improve pancreatic beta cell function (p=0.0074)...

Read the full 220 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >